Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company’s mission of connecting innovation to purpose. Dr. Brake will build upon Corbus’ commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation.
Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, including serving as Vice President, Global Project Leader in Oncology. In this position, she managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action. She is experienced in early- and late-stage clinical development, regulatory approvals (ALUNBRIG®, EXKIVITY™), program externalizations (DAY101, sapanisertib), and commercialization efforts. In her most recent role as the Head, U.S. Medical Affairs, in the Oncology Business Unit, Dr. Brake developed a medical strategy for Takeda Oncology’s portfolio and emerging immune-focused pipeline. Prior to her tenure at Takeda, Dr. Brake held leadership roles in Research at Amgen Inc. and Millennium Pharmaceuticals, Inc.
Dr. Brake will be responsible for advancing Corbus’ pipeline of TGFβ-targeting therapeutics as well as current endocannabinoid system targeting drug candidates. She will also play a key role in shaping the Company’s broader scientific strategy to help guide future business development opportunities and refinement of the research scope for the Company.
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus said, “Rachael brings a depth of industry experience coupled with a genuine passion for oncology drug development. Her expertise, leadership and vision will be critical to advancing our existing pipeline and supporting its expansion.”
Dr. Brake added, “I am excited to join Corbus and chart its scientific vision. The acquisition of CRB-601 will enable us to measure the impact of selectively inhibiting TGFβ in combination with immune checkpoint inhibitors and whether that overcomes the limitation of a ‘cold’ tumor microenvironment. I believe the integrins hold significant promise in immuno-oncology. I also look forward to expanding the new Corbus pipeline and leveraging the team’s proven expertise in executing complex, global clinical trials.”
Alan Holmer, Chairman of Corbus’ Board of Directors said, “We are pleased to welcome Rachael to Corbus. We look forward to benefiting from her innovative drug discovery and development experience to bring new therapies to patients.”
Dr. Brake obtained her Ph.D. in Molecular Biology and Biochemistry from the University of Western Australia Perth.
Companies In This Post
- Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Read more
- iCRYO Announces Partnership with Therapeutic Manufacturer, BTL Read more
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis Read more
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease Read more
- Poseida Therapeutics Announces Board Change Read more